Abstract
Introduction
Geriatric assessment (GA) for older patients with lung cancer could provide insight into vulnerability, cognitive impairment, and risk of toxicity. Discontinuation and complications of intensive treatment could potentially be prevented in vulnerable and frail patients. This study aimed to evaluate current clinical practice of GA for older patients with lung cancer in the Netherlands and identify potential hurdles for implementation.
Methods
Pulmonologists and radiation oncologists participating in the NVALT25-ELDAPT trial completed an online questionnaire regarding current practice of GA, added value of GA for treatment decision-making and logistic barriers for patients with non-small cell lung cancer.
Results
15 out of 17 centers responded. Three performed GA as standard procedure, three on indication, eight considered a frailty screening step before GA, and one did not perform GA. Suspicion of cognitive problems was mentioned most often as indication for GA and of added value for treatment decision-making, followed by older age, curative-intent treatment, and stage I–III lung cancer. Administered instruments for screening and extensive GA were diverse. Main barriers to implement GA in clinical practice were logistic problems (timescales and availability of trained personnel).
Conclusion
The use of GA in clinical practice for patients with lung cancer varied widely across centers regarding instruments and domains. Physicians are uniform in their opinion about indications for GA and the added value for treatment decision-making. Research should focus on manageable instruments and important domains to assess for this heterogeneous group of older patients with lung cancer to optimize treatment selection.
Trial registration The NVALT25-ELDAPT trial is registered under trial number NCT02284308. Details are available at http://www.eldapt.org (predominantly in Dutch).
Similar content being viewed by others
Notes
The NVALT25-ELDAPT trial is registered under trial number NCT02284308. Details are available at http://www.eldapt.org (predominantly in Dutch).
Abbreviations
- ADL:
-
Activities of daily living
- CHRT:
-
Chemoradiotherapy
- ELDAPT:
-
Elderly with locally advanced lung cancer: deciding through geriatric Assessment on the oPtimal Treatment strategy
- GA:
-
Geriatric assessment
- GFI:
-
Groningen frailty indicator
- GP:
-
General practitioner
- ICF:
-
International classification of functioning
- IADL:
-
Incremental activities of daily living
- MMSE:
-
Mini-mental state examination
- MNA:
-
Mini nutritional assessment
- NSCLC:
-
Non-small cell lung cancer
- NVALT25:
-
Dutch association of medical specialists for lung disease and tuberculosis (study number 25)
- PS:
-
Performance status
- SPPB:
-
Short physical performance battery
References
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz J-P, Lichtman S, Mor V, Monfardini S et al (2005) Use of comprehensive geriatric assessment in older cancer patients. Crit Rev Oncol Hematol 55(3):241–252
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, Falandry C, Artz A et al (2014) International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603
Hamaker ME, Wildes TM, Rostoft S (2017) Time to stop saying geriatric assessment is too time consuming. J Clin Oncol 35(25):2871–2874
Schulkes KJG, Hamaker ME, van den Bos F, van Elden LJR (2016) Relevance of a geriatric assessment for elderly patients with lung cancer—a systematic review. Clin Lung Cancer 17(5):341–349.e3
Gosney MA (2005) Clinical assessment of elderly people with cancer. Lancet Oncol 6(10):790–797
Driessen EJ, Aarts MJ, Bootsma GP, van Loon JG, Janssen-Heijnen ML (2017) Trends in treatment and relative survival among non-small cell lung cancer patients in the Netherlands (1990–2014): disparities between younger and older patients. Lung Cancer 108:198–204
Schulkes KJG, Souwer ETD, Hamaker ME, Codrington H, van der Sar-van der Brugge S, Lammers JWJ, Portielje JEA, van Elden LJR et al (2017) The effect of a geriatric assessment on treatment decisions for patients with lung cancer. Lung 195(2):225–231
Corre R, Greillier L, Caër HL, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non–small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08–02 Study. J Clin Oncol 34(13):1476–1483
Aupérin A, Le CP, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190
Driessen EJ, Bootsma GP, Hendriks LE, van den Berkmortel FW, Bogaarts BA, van Loon JG, Dingemans AC, Janssen-Heijnen ML (2016) Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol 121(1):26–31
Driessen EJM, Schulkes KJG, Dingemans A-MC, van Loon JGM, Hamaker ME, Aarts MJ, Janssen-Heijnen MLG (2018) Patterns of treatment and survival among older patients with stage III non-small cell lung cancer. Lung Cancer 116:55–61
Cardenal F, Nadal E, Jové M, Faivre-Finn C (2015) Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. Ann Oncol 26(2):278–288
Gridelli C, Langer C, Maione P, Rossi A, Schild SE (2007) Lung cancer in the elderly. J Clin Oncol 25(14):1898–1907
Semrau S, Zettl H, Hildebrandt G, Klautke G, Fietkau R (2014) Older patients with inoperable non-small cell lung cancer. Strahlenther Onkol 190(12):1125–1132
Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F et al (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non—small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872
Decoster L, Kenis C, Schallier D, Vansteenkiste J, Nackaerts K, Vanacker L, Vandewalle N, Flamaing J et al (2017) Geriatric assessment and functional decline in older patients with lung cancer. Lung 195(5):619–626
Blanco R, Maestu I, de la Torre MG, Cassinello A, Nunez I (2015) A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol 26(3):451–463
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101
Kale MS, Mhango G, Gomez JE, Sigel K, Smith CB, Bonomi M, Wisnivesky JP (2017) Treatment toxicity in elderly patients with advanced non-small cell lung cancer. Am J Clin Oncol 40(5):470–476
Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T et al (2013) Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 24(5):1306–1312
Puts MTE, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, Springall E, Alibhai SMH (2014) An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol 25(2):307–315
Wedding U, Ködding D, Pientka L, Steinmetz HT, Schmitz S (2007) Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol/Hematol 64(1):1–9
Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 26(2):288–300
Smets IH, Kempen GI, Janssen-Heijnen ML, Deckx L, Buntinx FJ, van den M, Akker (2014) Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. BMC Geriatr 14:26
Nie X, Liu D, Li Q, Bai C. Predicting chemotherapy toxicity in older adults with lung cancer. Journal of Geriatric Oncology 2013 4(4):334–339
Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for high-age patients (CRASH) score. Cancer 118(13):3377–3386
Ackroyd S, Hughes JA (1981) Data collection in context. In: Series aspects of modern sociology. Longman, London
Acknowledgements
All authors made substantial contributions to the design of the questionnaire, proofreading the manuscript, revising the contents critically, and approving the final version before publication. ED additionally contributed in the distribution, collection, analysis, and interpretation of the data, and drafting the article. We would like to thank Dr. K Smits, Dr. Y Lievens, Dr. M Joore, Dr. B Ramaekers, Dr. F van den Berkmortel, Dr. A Berlanga, R Houben, Dr. A. Dekker, and other project team members for their insights, expertise, and time invested in the development and implementation of the NVALT25-ELDAPT trial.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Driessen, E.J.M., van Loon, J.G.M., Maas, H.A. et al. Geriatric Assessment for Older Patients with Non-small Cell Lung Cancer: Daily Practice of Centers Participating in the NVALT25-ELDAPT Trial. Lung 196, 463–468 (2018). https://doi.org/10.1007/s00408-018-0116-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-018-0116-8